ClinicalTrials.gg
Sign In

Otitis Media clinical trials

The registry lists 241 studies for Otitis Media across more than 10 countries. 32 are recruiting or about to start. 175 of them are mainly about Otitis Media (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its narrower condition Otitis Media with Effusion too: 296 studies, 38 open.

Get an email when these change. Save the Otitis Media studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
153
Status unknown
21
Recruiting
20
Terminated
15
Not yet recruiting
12
Active, not recruiting
12

Phase

Phase 3
48
Phase 2
22
Phase 4
21
Phase 1
9
Early Phase 1
1

Where

United States
110
Canada
12
Finland
10
Israel
10
Australia
8
France
7

Who runs them

GlaxoSmithKline (11) · Alcon Research (10) · Integra LifeSciences Corporation (8) · University of Pittsburgh (8) · Pfizer (7) · Menzies School of Health Research (5) · Children's Hospital of Philadelphia (5) · Otonomy, Inc. (5)

What is being tested here

Drugs under test in Otitis Media studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Amoxicillin218
Clavulanic Acid215
Triamcinolone Acetonide111
Triamcinolone111
PHiD-CV vaccine045
Azithromycin035
Benzocaine024
Moxifloxacin034
Dexamethasone phosphate034
Dexamethasone034

Drug classes tested here Beta-lactamase inhibitors 2 open · Corticosteroids 1 open · Local anesthetics 5

Coming up

1phase 3 study under way
14studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger. 19 (95%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (20%) take healthy volunteers.

Recruiting studies that take each age, of 20
AgeWomenMen
1011 (55%)11 (55%)
187 (35%)7 (35%)
305 (25%)5 (25%)
405 (25%)5 (25%)
505 (25%)5 (25%)
655 (25%)5 (25%)
755 (25%)5 (25%)
855 (25%)5 (25%)

Across all 241 studies, recruiting or not: 80% stop at 75 or younger and 77% at 65; 85% take children; 2% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Otitis Media studies take

Of 10 phase 3 interventional studies under Otitis Media, half reached primary completion within 15 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 315 mo11–35 · 10 studies——
Interventional, no phase38 mo13–51 · 45 studies—38 mo11–64 · 36 studies
Observational24 mo18–67 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 12, 2026.

Started recruiting1

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 241. Browse all 241 → or search them.